+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Targeted Radiotherapy Drug Market - Global Forecast 2026-2032- Product Image
Targeted Radiotherapy Drug Market - Global Forecast 2026-2032- Product Image
Sale

Targeted Radiotherapy Drug Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6142099
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Targeted Radiotherapy Drug Market is projected to reach USD 6.34 Billion in 2026. It is expected to continue growing at a CAGR of 5.97%, reaching USD 8.98 Billion by 2032.

Targeted Radiotherapy Drugs: Executive Overview

Targeted radiotherapy drugs combine a radiation-emitting payload with a targeting mechanism designed to concentrate treatment near selected biological markers. Their clinical relevance is shaped by tumor biology, diagnostic imaging, radiopharmaceutical handling, patient selection, dosimetry, and access to specialized treatment infrastructure. Evaluation of this field therefore requires attention to both therapeutic innovation and the operational systems needed to deliver safe, individualized care.

Clinical and Operational Shifts Reshaping Targeted Radiotherapy

The landscape is shifting toward more precise patient selection, integrated imaging-and-treatment pathways, and treatment approaches that seek to balance tumor control with reduced exposure to healthy tissue. Advances in biomarker testing, nuclear medicine, radiopharmacy, automated dose preparation, and multidisciplinary care are influencing how therapies are evaluated and delivered. At the same time, short-lived radioactive materials create distinctive requirements for manufacturing, transport, scheduling, regulatory compliance, waste management, and treatment-center coordination.

Artificial Intelligence Across Discovery, Selection, and Delivery

Artificial intelligence can support targeted radiotherapy by improving image interpretation, identifying clinically relevant biomarkers, assisting lesion segmentation, and helping clinicians assess treatment suitability. It may also contribute to dosimetry, response monitoring, workflow optimization, and quality control in radiopharmacy. Responsible adoption requires representative training data, prospective validation, explainable outputs, cybersecurity safeguards, human oversight, and clear accountability for clinical decisions. AI is best treated as a decision-support capability rather than a substitute for specialist judgment.

Regional Insights: Infrastructure, Access, and Regulatory Readiness

North America combines advanced oncology infrastructure, established nuclear medicine capabilities, and active clinical research, while access can vary by reimbursement policy, geography, and availability of specialized centers. Europe benefits from strong academic networks and coordinated scientific standards, although national authorization, payment, and logistics systems differ. Asia-Pacific includes sophisticated healthcare systems alongside rapidly expanding capacity, with Japan, Australia, China, India, and South Korea each presenting distinct regulatory and infrastructure conditions. Latin America is influenced by uneven access to imaging, radiopharmacy, and specialist care, making referral networks and supply reliability important. The Middle East is investing in advanced oncology services, particularly in major urban centers, while the broader region faces differences in workforce depth and treatment access. Africa shows substantial variation between countries; improving radiotherapy infrastructure, diagnostic capacity, isotope supply, and specialist training remains central to broader availability.

Group Insights: Cooperation and Divergent Health-System Conditions

ASEAN markets differ in regulatory maturity, treatment capacity, and access to nuclear medicine, creating opportunities for shared training, referral pathways, and harmonized technical practices. BRICS members span highly developed and resource-constrained settings, so domestic manufacturing, isotope security, affordability, and workforce development are recurring priorities. The European Union supports collaboration through common scientific frameworks while retaining national differences in reimbursement and healthcare delivery. G7 countries generally possess strong research, regulatory, and clinical infrastructure, but must address affordability, capacity constraints, and equitable access. GCC states are expanding specialist healthcare capabilities and can benefit from coordinated procurement, workforce development, and regional referral systems. NATO members represent a diverse health-system group; cooperation in supply resilience, emergency preparedness, and scientific exchange may strengthen continuity for radiopharmaceutical services.

Country Insights: Diverse Pathways to Adoption and Access

The United States and Canada have substantial oncology research and specialized treatment capacity, with access shaped by reimbursement, referral patterns, and geographic concentration. Germany, France, Italy, Spain, and the United Kingdom combine advanced clinical expertise with differing assessment, procurement, and payment processes. Australia benefits from strong clinical standards but must manage distance, isotope logistics, and concentration of specialist services. Japan and South Korea have sophisticated healthcare and imaging ecosystems, while China is expanding domestic research, manufacturing, and specialist capacity within a distinct regulatory environment. India is developing advanced oncology services alongside persistent access and infrastructure gaps. Brazil and Mexico are strengthening specialized care but face regional disparities in equipment, trained personnel, and treatment availability. Russia maintains scientific and medical capabilities, with access influenced by regulatory, supply-chain, and infrastructure conditions.

Leadership Priorities for Safe and Scalable Clinical Adoption

Industry leaders should build strategies around validated biomarkers, reliable isotope and component supply, and partnerships with treatment centers capable of imaging, dosimetry, administration, and follow-up. They should engage regulators and payers early, generate evidence that reflects routine clinical populations, and establish transparent protocols for patient selection, radiation safety, adverse-event management, and long-term monitoring. Operational resilience should include qualified radiopharmacy capacity, contingency logistics, workforce training, and digital traceability. Leaders should also apply AI selectively, with governance processes that protect patient data and verify performance across demographic and clinical subgroups.

Research Methodology for the Executive Assessment

This executive assessment uses the defined targeted radiotherapy drug category as its analytical scope and organizes findings around clinical, technological, operational, regulatory, and geographic dimensions. It synthesizes established public-domain knowledge about targeted radiopharmaceutical development, nuclear medicine workflows, oncology care delivery, imaging, dosimetry, and health-system requirements. Regional, group, and country observations are presented qualitatively to highlight structural differences without introducing market estimates, market sizing, market shares, forecasts, or unsupported comparative rankings. Interpretation should be updated as clinical evidence, regulatory decisions, infrastructure, and supply conditions evolve.

Conclusion: Precision Requires Integrated Evidence and Delivery Systems

Targeted radiotherapy drugs are advancing within a broader shift toward biologically informed, image-guided, and more individualized cancer care. Their successful adoption depends not only on therapeutic performance, but also on diagnostic readiness, isotope and radiopharmacy infrastructure, specialist expertise, reimbursement, safety systems, and equitable referral pathways. Organizations that connect clinical evidence with dependable delivery capabilities, responsible AI governance, and region-specific implementation planning will be better positioned to translate scientific progress into safe patient care.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid expansion of lutetium-177 radiopharmaceutical production capacity in response to growing clinical demand
5.2. Increasing partnerships between biotech firms and academic centers for novel alpha-emitter targeted therapy development
5.3. Emergence of precision dosimetry software solutions integrating radiomics and artificial intelligence algorithms
5.4. Regulatory acceleration of theranostic agents through breakthrough designations and priority review pathways
5.5. Rising investment in CAR-T combined with radioconjugates for enhanced hematologic cancer treatment efficacy
5.6. Expansion of personalized treatment protocols for neuroendocrine tumors using targeted radioligand therapy
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Targeted Radiotherapy Drug Market, by Indication
8.1. Introduction
8.2. Bone Metastasis
8.3. Liver Cancer
8.4. Neuroendocrine Tumors
8.5. Prostate Cancer
8.5.1. Metastatic Castration Resistant Prostate Cancer
8.5.2. Metastatic Hormone Sensitive Prostate Cancer
9. Targeted Radiotherapy Drug Market, by Mechanism Of Action
9.1. Introduction
9.2. Radioimmunotherapy
9.2.1. Alpha Radioimmunoconjugates
9.2.2. Beta Radioimmunoconjugates
9.3. Radioligand Therapy
9.3.1. Peptide Receptor Radionuclide Therapy
9.3.2. Psma Radioligand Therapy
10. Targeted Radiotherapy Drug Market, by Radionuclide Type
10.1. Introduction
10.2. Alpha Emitters
10.2.1. Actinium 225
10.2.2. Radium 223
10.3. Beta Emitters
10.3.1. Lutetium 177
10.3.2. Yttrium 90
11. Targeted Radiotherapy Drug Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Cancer Treatment Centers
11.4. Hospitals
12. Americas Targeted Radiotherapy Drug Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Targeted Radiotherapy Drug Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Targeted Radiotherapy Drug Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Novartis AG
15.3.2. Bayer AG
15.3.3. Telix Pharmaceuticals Limited
15.3.4. Lantheus Holdings, Inc.
15.3.5. RayzeBio, Inc.
15.3.6. Actinium Pharmaceuticals, Inc.
15.3.7. ITM Isotope Technologies Munich SE
15.3.8. Curium SAS
15.3.9. Nordion Inc.
15.3.10. Advanced Accelerator Applications SA
16. Research AI17. Research Statistics18. Research Contacts19. Research Articles20. Appendix
List of Figures
FIGURE 1. TARGETED RADIOTHERAPY DRUG MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. TARGETED RADIOTHERAPY DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. TARGETED RADIOTHERAPY DRUG MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. TARGETED RADIOTHERAPY DRUG MARKET: RESEARCHAI
FIGURE 24. TARGETED RADIOTHERAPY DRUG MARKET: RESEARCHSTATISTICS
FIGURE 25. TARGETED RADIOTHERAPY DRUG MARKET: RESEARCHCONTACTS
FIGURE 26. TARGETED RADIOTHERAPY DRUG MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. TARGETED RADIOTHERAPY DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BONE METASTASIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BONE METASTASIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY LIVER CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY METASTATIC CASTRATION RESISTANT PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY METASTATIC CASTRATION RESISTANT PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY METASTATIC HORMONE SENSITIVE PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY METASTATIC HORMONE SENSITIVE PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA RADIOIMMUNOCONJUGATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA RADIOIMMUNOCONJUGATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA RADIOIMMUNOCONJUGATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA RADIOIMMUNOCONJUGATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PEPTIDE RECEPTOR RADIONUCLIDE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PEPTIDE RECEPTOR RADIONUCLIDE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PSMA RADIOLIGAND THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PSMA RADIOLIGAND THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ACTINIUM 225, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ACTINIUM 225, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIUM 223, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIUM 223, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY LUTETIUM 177, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY LUTETIUM 177, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY YTTRIUM 90, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY YTTRIUM 90, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 109. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 110. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 111. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 112. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 113. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 114. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 115. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 116. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 117. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 118. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 119. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 120. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 121. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 122. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 123. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 124. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 125. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. CANADA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 128. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 129. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 130. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 131. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 132. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 133. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 134. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 135. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 136. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 137. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 138. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 139. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 140. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 141. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 142. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 143. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. MEXICO TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 222. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 223. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 224. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 225. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 226. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 227. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 228. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 229. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 230. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 231. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 232. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 233. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 234. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 235. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. GERMANY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 238. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 239. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 240. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 241. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 242. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 243. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 244. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 245. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 246. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 247. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 248. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 249. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 250. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 251. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 252. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 253. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. FRANCE TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 256. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 257. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 258. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 259. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 260. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 274. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 275. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 276. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 277. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 278. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 279. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 280. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 281. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 282. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 283. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 284. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 285. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 286. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 287. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 288. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 289. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. ITALY TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 292. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 293. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 294. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 295. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 296. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 297. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 298. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOIMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 299. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2018-2024 (USD MILLION)
TABLE 300. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIOLIGAND THERAPY, 2025-2030 (USD MILLION)
TABLE 301. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2024 (USD MILLION)
TABLE 302. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY RADIONUCLIDE TYPE, 2025-2030 (USD MILLION)
TABLE 303. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2018-2024 (USD MILLION)
TABLE 304. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY ALPHA EMITTERS, 2025-2030 (USD MILLION)
TABLE 305. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2018-2024 (USD MILLION)
TABLE 306. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY BETA EMITTERS, 2025-2030 (USD MILLION)
TABLE 307. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 308. SPAIN TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES TARGETED RADIOTHERAPY DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD

Companies Mentioned

  • Actinium Pharmaceuticals, Inc.
  • Advanced Accelerator Applications SA
  • Bayer AG
  • Curium SAS
  • Eli Lilly and Company
  • ITM Isotope Technologies Munich SE
  • Lantheus Holdings, Inc.
  • Nordion Inc.
  • Novartis AG
  • RayzeBio, Inc.
  • Telix Pharmaceuticals Limited

Related Topics

Related Reports

Radiotherapy Market - Global Forecast 2026-2032 - Product Image

Radiotherapy Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Cancer Radiotherapy Market - Global Forecast 2026-2032 - Product Image

Cancer Radiotherapy Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
Radiotherapy Market Report 2026 - Product Image

Radiotherapy Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Radiotherapy Induced Oral Mucositis - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Radiotherapy Induced Oral Mucositis - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 200 Pages
  • Global
From
Systemic Radiotherapy - Global Strategic Business Report - Product Image

Systemic Radiotherapy - Global Strategic Business Report

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.